A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present
文献类型：期刊论文
| 作者 | Dong, Ze2; Huang, Yue1,2; Xia, Wenyang1; Liao, Yonggang4; Yang, Cai-Guang1,2,3
|
| 刊名 | EXPERT OPINION ON THERAPEUTIC PATENTS
 |
| 出版日期 | 2025-03-15 |
| 页码 | 10 |
| 关键词 | RNA methylation FTO inhibitors anticancer patents obesity |
| ISSN号 | 1354-3776 |
| DOI | 10.1080/13543776.2025.2477482 |
| 英文摘要 | Introduction: The fat mass and obesity-associated protein (FTO) catalytically demethylates RNA N6-methyl adenosine (m6A) modification, dynamically regulates gene expression in eukaryotes. Interestingly, FTO is highly expressed and functions as an oncogenic factor in a wide range of cancers. Therefore, using small-molecule inhibitors to target FTO has been established as a promising therapeutic strategy for combating cancers. Areas covered: Patent literature claiming novel chemical entities as FTO inhibitors disclosed from 2017 to present is available in Espacenet, including dozens of patent documents. Expert opinion: The pivotal influence of FTO demethylase in a particular epigenetic layer of regulation of gene expression renders it promising for FTO to be a therapeutical target for many diseases, including malignant cancers. Several institutions were prompted and have patented chemical frameworks as FTO inhibitors. Remarkedly, the FTO inhibitor CS1 (Bisantrene) has advanced to clinical trials for treating acute myeloid leukemia (AML). The successful advancement of CS1 into clinical trials would continuingly stimulate researches on RNA epigenetic enzymes targeted first-in-class anticancer drug discovery. |
| WOS关键词 | MULTICENTER PHASE-II ; BREQUINAR SODIUM ; RNA MODIFICATIONS ; GENE-EXPRESSION ; DEMETHYLASE ; CANCER ; DUP-785 ; TRIAL ; ACID |
| 资助项目 | National Key Research and Development Program of China[2023YFD1800102] ; National Natural Science Foundation of China[22077133] ; National Natural Science Foundation of China[22277127] ; Research Funds of Hangzhou Institute for Advanced Study, UCAS[2023HIAS-Y026] ; Research Funds of Hangzhou Institute for Advanced Study, UCAS[2023HIAS-V006] ; National Natural Science Foundation of China ; Research Funds of Hangzhou Institute for Advanced Study, UCAS |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001446961500001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/316689]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Yang, Cai-Guang |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China 2.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, 1 Sub Lane Xiangshan, Hangzhou 310024, Zhejiang, Peoples R China 3.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai, Peoples R China 4.Rname Pharmaceut Technol Shanghai Co LTD, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Dong, Ze,Huang, Yue,Xia, Wenyang,et al. A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present[J]. EXPERT OPINION ON THERAPEUTIC PATENTS,2025:10. |
| APA | Dong, Ze,Huang, Yue,Xia, Wenyang,Liao, Yonggang,&Yang, Cai-Guang.(2025).A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present.EXPERT OPINION ON THERAPEUTIC PATENTS,10. |
| MLA | Dong, Ze,et al."A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present".EXPERT OPINION ON THERAPEUTIC PATENTS (2025):10. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。